transcript   Transcript

Arbitration in Life Sciences Transaction Disputes

Recorded on: Aug. 22, 2018
Running Time: 01:00:40

Full Transcript:



If you are a Privileged Member, just log in and start reading now! If you are not a Privileged Member, please click here to learn how unlimited access to PLI programs may be right for you and your firm.

To access the streaming media of this presentation, please purchase the corresponding seminar segment.

Taken from the Audio-only Briefing Arbitration in Life Sciences Transaction Disputes Recorded August 2018 in New York

Arbitration in Life Sciences Transaction Disputes [01:00:40]

Arbitration is rapidly becoming the preferred dispute resolution mechanism for the life sciences sector.  There are numerous reasons for this.  The most obvious is that increasingly M&A transactions are cross-border (e.g. Takeda’s acquisition of Shire).  The often complex lengthy process involved in life science transactions can give rise to dispute at various stages.

Please join Haig Oghigian, F.C.I.Arb. of Squire Patton Boggs LLP as he addresses:
  • The law applicable to each agreement is expressly stated in most Life Sciences transaction contracts. Difficult issues arise, however, where it is not. These mostly arise in the pre-signing phase, usually before the execution of a letter of intent ("LOI") This might occur if the parties felt that choosing an applicable law was unnecessary in an LOI or inappropriate, since it might imply that the document has legal effects that the parties did not intend the LOI to have.
  • Here, as well, problems can arise, including: (a) what is a competent court if it is not specified in the relevant document (L0I or agreement); (b) whether an arbitration clause is valid, whether it extends only to other companies of the groups to which the parties belong; and (c) whether a particular issue falls within the scope of the arbitration clause.
  • Interim relief may also play an essential role in Life Sciences transaction disputes by preventing behavior that could have irremediable consequences, such as the breach of a confidentiality or exclusivity clause or, most importantly, the completion of a proposed transaction with another party.
  • Specific performance is difficult topic, the main question being whether the implementation of a proposed transaction can be ordered by a judge or arbitral tribunal. The answer is likely to depend on the circumstances and the stage at which the issue arises.

In the pre-signing phase, it is difficult to imagine where a court could issue an order to sign an agreement especially if the terms and conditions have not been at least substantially agreed upon.

At the post-signing but pre-closing stage, specific performance could be envisaged, but not without carefully taking into account the nature of the transaction. Ordering the assignment of 100 per cent of the shares of a holding company might, for example, be not too problematic. On the other hand, ordering parties to set up and manage a joint venture can be expected to be more problematic.

Program Level: Overview

Intended Audience: Attorneys and allied professionals who counsel pharmaceutical and life sciences companies

Prerequisites: A familiarization with life sciences law, litigation and regulation

Advanced Preparation: None 

Presentation Material
  • Arbitration in Life Sciences Transaction Related Disputes
    Haig Oghigian
  • Share
    Email
    Transcript FAQ's
    • How Can I Access Transcripts?
      You must be a Member in good standing.

    • Can I access the Video?
      Yes, you can access the video if you have the Adobe Flash plugin installed. Click on the video camera icon when you mouse over each paragraph. The media will begin playback at that point.

    • Can I get CLE credit for reading the transcript?
      No, CLE credit cannot be earned for reading a transcript. CLE credit is issued only for verified attendance while watching a web program. If seeking credit, please verify the program's eligibility for credit and expiration date in your jurisdiction on the web segment launch page before commencing the program.
    
    • FOLLOW PLI:
    • twitter
    • LinkedIn
    • YouTube
    • RSS

    All Contents Copyright © 1996-2019 Practising Law Institute. Continuing Legal Education since 1933.

    © 2019 PLI PRACTISING LAW INSTITUTE. All rights reserved. The PLI logo is a service mark of PLI.